Neurocrine Biosciences Inc (FRA:NB3)
€ 128.95 -0.2 (-0.15%) Market Cap: 13.01 Bil Enterprise Value: 12.37 Bil PE Ratio: 38.40 PB Ratio: 5.88 GF Score: 89/100

Q2 2020 Neurocrine Biosciences Inc Earnings Call Transcript

Aug 03, 2020 / 08:30PM GMT
Release Date Price: €104.15 (+2.97%)
Operator

Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Second Quarter 2020 Results. (Operator Instructions)

It is now my pleasure to turn today's conference over to Todd Tushla, VP of Investor Relations. Please go ahead.

Todd Tushla;Kevin C. Gorman
Neurocrine Biosciences, Inc. - VP of IR;Neurocrine Biosciences, Inc. - CEO &amp

Thank you, Ryland. Good afternoon, everyone, and thank you for joining our Q2 2020 Earnings Call. Joining me on the call is Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.

During today's call, we'll be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings.

With that, I now turn the call over to Kevin.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot